ASX Announcements.
Date | Price sens. | Headline | pages | |
---|---|---|---|---|
26/10/2021 | Notice of Annual General Meeting/Proxy Form | 25 | ||
26/10/2021 | Appendix 4G | 14 | ||
26/10/2021 | Annual Report to shareholders | 86 | ||
26/10/2021 | Annual Report filed on Form 20-F with SEC | 177 | ||
12/10/2021 | 2021 Annual General Meeting and Key Dates | 2 | ||
07/10/2021 | Ceasing to be a substantial holder from AEF | 4 | ||
04/10/2021 | Change of Director's Interest Notice - Mr Chamberlain | 3 | ||
04/10/2021 | Change of Director's Interest Notice - Mr Meyers | 3 | ||
04/10/2021 | Immutep to present Phase II TACTI-002 data at SITC 2021 | 3 | ||
01/10/2021 | Notification regarding unquoted securities - IMM | 6 | ||
01/10/2021 | Application for quotation of securities - IMM | 6 | ||
29/09/2021 | ! | Immutep Receives A$3.4 million R&D French Tax Incentive | 2 | |
28/09/2021 | Immutep to Present at Healthcare Investor Conferences | 1 | ||
27/09/2021 | Immutep Corporate Presentation | 46 | ||
21/09/2021 | Immutep to present final Overall Survival data from Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021 | 2 | ||
01/09/2021 | ! | Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002 | 3 | |
31/08/2021 | ! | Immutep's Partner, EOC Pharma, Expands Efti Trial Pipeline | 2 | |
30/08/2021 | ! | Appendix 4E & 2021 Full Year Statutory Accounts | 86 | |
27/08/2021 | ! | Chinese patent granted for anti-LAG-3 antibody LAG525 | 2 | |
05/08/2021 | ! | INSIGHT-003 investigator-initiated trial - 1st patient dosed | 2 | |
03/08/2021 | Becoming a substantial holder | 3 | ||
03/08/2021 | Change in substantial holding | 6 | ||
30/07/2021 | Cleansing Notice | 1 | ||
30/07/2021 | ! | Completion of Placement - Tranche 2 | 2 | |
29/07/2021 | Application for quotation of securities - IMM | 5 | ||
27/07/2021 | Change in substantial holding | 6 | ||
27/07/2021 | Proposed issue of securities - IMM | 5 | ||
26/07/2021 | Results of EGM | 2 | ||
26/07/2021 | Chairman's EGM Address | 2 | ||
26/07/2021 | 2021 EGM Presentation | 24 | ||
23/07/2021 | Application for quotation of securities - IMM | 6 | ||
23/07/2021 | Change in substantial holding | 6 | ||
21/07/2021 | Completion of Share Purchase Plan | 2 | ||
15/07/2021 | EGM - Now to be Held as an Online Virtual Meeting | 2 | ||
13/07/2021 | ! | Immutep Quarterly Activities Report & Appendix 4C | 9 | |
06/07/2021 | ! | US FDA & IRB approves start of ph2b head & neck cancer trial | 2 | |
05/07/2021 | Proposed issue of securities - IMM | 7 | ||
30/06/2021 | Change in substantial holding from AEF | 4 | ||
30/06/2021 | Change in substantial holding | 6 | ||
28/06/2021 | Cleansing Notice | 1 | ||
25/06/2021 | Notice of Extraordinary General Meeting/Proxy Form | 12 | ||
25/06/2021 | Share Purchase Plan Offer Documents | 15 | ||
25/06/2021 | Application for quotation of securities - IMM | 5 | ||
21/06/2021 | ! | Efti to be evaluated in new triple combination therapy trial | 2 | |
21/06/2021 | Proposed issue of securities - IMM | 5 | ||
21/06/2021 | ! | Immutep Capital Raising Presentation | 61 | |
21/06/2021 | ! | Immutep secures commitments for A$60 million in a Placement | 4 | |
17/06/2021 | ! | Trading Halt | 2 | |
15/06/2021 | Change in substantial holding | 6 | ||
08/06/2021 | Appendix 2A | 6 | ||
08/06/2021 | ! | Immutep Reveals a New anti-LAG-3 Research Program | 2 | |
07/06/2021 | Application for quotation of securities - IMM | 6 | ||
04/06/2021 | Immutep Presentation for Jefferies Healthcare Conference | 33 | ||
04/06/2021 | ! | Immutep Reports Positive Data from its TACTI-002 Ph 2 trial | 5 | |
04/06/2021 | ! | Immutep Reports Positive Final Data from INSIGHT-004 trial | 3 | |
02/06/2021 | ! | Immutep Granted European Patent for its LAG-3 Candidate Efti | 2 | |
01/06/2021 | ! | Immutep Enters New Collaboration with Merck KGaA for Efti | 2 | |
26/05/2021 | ! | Immutep Granted Chinese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination | 2 | |
25/05/2021 | Immutep to Present at Jefferies Healthcare Conference | 1 | ||
20/05/2021 | TACTI-002 and INSIGHT-004 abstracts for ASCO 2021 | 2 | ||
20/05/2021 | Change in substantial holding | 6 | ||
18/05/2021 | Change in substantial holding | 6 | ||
14/05/2021 | Appendix 2A | 16 | ||
13/05/2021 | Immutep Corporate Presentation | 48 | ||
07/05/2021 | ! | Operational Update | 3 | |
29/04/2021 | ! | TACTI-002 & INSIGHT-004 data to be presented at ASCO | 2 | |
19/04/2021 | ! | Immutep Quarterly Activities Report & Appendix 4C | 9 | |
16/04/2021 | ! | Immutep Receives A$1,155,055 R&D Tax Incentive | 1 | |
14/04/2021 | Immutep Investor Update | 20 | ||
08/04/2021 | ! | Immutep Achieves Fast Track Designation for Efti from US FDA | 2 | |
07/04/2021 | ! | Immutep Announces European Patent Grant For LAG525 | 2 | |
01/04/2021 | Change in substantial holding | 6 | ||
18/03/2021 | Appendix 2A | 16 | ||
16/03/2021 | ! | Immutep Collaborates with MSD for Phase IIB Head & Neck Trial | 2 | |
12/03/2021 | ! | S&P DJI Announces March 2021 Quarterly Rebalance | 9 | |
09/03/2021 | ! | Immutep Secures Second US Patent Grant for Eftilagimod Alpha | 2 | |
05/03/2021 | ! | Immutep Expands Part B of TACTI-002 Collaboration Trial | 2 | |
23/02/2021 | ! | Half Yearly Report and Accounts | 30 | |
02/02/2021 | Immutep Corporate Presentation | 45 | ||
27/01/2021 | ! | IMM - Phase II Study for Eftilagimod Alpha in COVID-19 advances | 2 | |
22/01/2021 | ! | Immutep Quarterly Activities Report & Appendix 4C | 10 | |
22/01/2021 | ! | Ulcerative Colitis Phase II Study of GSK2831781 Discontinued | 2 | |
07/01/2021 | ! | Recruitment of Head & Neck Cancer Patients Completed for Ph2 | 2 | |
04/01/2021 | Resignation and Appointment of Joint Company Secretary | 1 | ||
04/01/2021 | Change in substantial holding | 10 | ||
31/12/2020 | Appendix 2A | 16 | ||
31/12/2020 | Change in substantial holding | 6 | ||
30/12/2020 | Change in substantial holding | 8 | ||
30/12/2020 | ! | Immutep granted US patent for Eftilagimod alpha with a PD-1 | 2 | |
29/12/2020 | Change in substantial holding | 8 | ||
24/12/2020 | Change of Director's Interest Notice - Dr Howard | 3 | ||
24/12/2020 | Appendix 2A | 16 | ||
24/12/2020 | Becoming a substantial holder | 9 | ||
18/12/2020 | Change in substantial holding | 6 | ||
17/12/2020 | Change in substantial holding | 6 | ||
16/12/2020 | ! | Immutep Upscales Efti Manufacturing | 2 | |
16/12/2020 | Change in substantial holding | 6 | ||
15/12/2020 | ! | Operational Update | 2 | |
15/12/2020 | Ceasing to be a substantial holder | 1 | ||
15/12/2020 | Change in substantial holding | 6 | ||
11/12/2020 | Appendix 2A | 16 | ||
10/12/2020 | ! | Immutep's partner EOC Pharma to start Ph II trial in MBC | 2 | |
10/12/2020 | ! | Overall Survival Data from Ph IIb AIPAC Breast Cancer trial | 4 | |
27/11/2020 | Change in substantial holding | 6 | ||
25/11/2020 | Cleansing Notice | 1 | ||
24/11/2020 | Change of substantial holding from AEF | 4 | ||
24/11/2020 | Appendix 2A | 16 | ||
19/11/2020 | ! | Proposed issue of Securities - IMM | 5 | |
19/11/2020 | Immutep Investor Presentation | 52 | ||
19/11/2020 | ! | Immutep completes a A$29.6 million placement | 3 | |
19/11/2020 | ! | Immutep expands TACTI-002 Collaboration Trial with MSD | 3 | |
18/11/2020 | Change in substantial holding | 6 | ||
17/11/2020 | ! | Trading Halt | 2 | |
17/11/2020 | ! | Pause in Trading | 1 | |
10/11/2020 | ! | Encouraging Phase II TACTI-002 Data Reported at SITC 2020 | 5 | |
09/11/2020 | ! | Immutep Announces Australian Patent Grant for IMP701 | 2 | |
06/11/2020 | Change of Director's Interest Note - Grant Chamberlain | 3 | ||
06/11/2020 | Appendix 3G | 15 | ||
06/11/2020 | Proposed issue of Securities - IMM | 5 | ||
03/11/2020 | Immutep to present TACTI-002 phase 2 data at SITC 2020 | 2 | ||
02/11/2020 | Lapse of Unlisted Options | 1 | ||
30/10/2020 | ! | Immutep enters into a Licence & Collaboration with LabCorp | 2 | |
27/10/2020 | Results of Meeting | 2 | ||
27/10/2020 | Immutep AGM 2020 - Chairman's Address | 3 | ||
27/10/2020 | ! | Immutep AGM 2020 - CEO Marc Voigt's Presentation | 21 | |
23/10/2020 | ! | COVID-19 phase 2 investigator initiated trial commences | 4 | |
22/10/2020 | ! | Immutep Quarterly Activities Report & Appendix 4C | 9 | |
21/10/2020 | ! | Immutep granted European patent for IMP761 | 2 | |
19/10/2020 | Immutep to present AIPAC Overall Survival data at SABCS 2020 | 2 | ||
06/10/2020 | Change in substantial holding | 6 | ||
05/10/2020 | Appendix 3Y - Change of Director's Interest Notice - Mr Chamberlain | 3 | ||
05/10/2020 | Appendix 3Y - Change of Director's Interest Notice - Mr Meyers | 3 | ||
05/10/2020 | Appendix 3Y - Change of Director's Interest Notice - Mr Voigt | 3 | ||
02/10/2020 | Appendix 2A | 17 | ||
02/10/2020 | Appendix 3G | 15 | ||
28/09/2020 | Annual Report filed on Form 20-F with SEC | 137 | ||
25/09/2020 | Notice of Annual General Meeting/Proxy Form | 28 | ||
25/09/2020 | Appendix 4G & Corporate Governance Statement | 35 | ||
25/09/2020 | Annual Report to shareholders | 87 | ||
18/09/2020 | ! | Immutep reports improving results from INSIGHT-004 trial | 3 | |
18/09/2020 | ! | Improving results from stage 1 of TACTI-002 Ph II trial | 4 | |
14/09/2020 | Change in substantial holding | 6 | ||
11/09/2020 | 2020 Annual General Meeting and Key Dates | 2 | ||
31/08/2020 | ! | IMM and Monash Uni receive funding grant for LAG-3 Research | 2 | |
26/08/2020 | New data to be presented at ESMO for eftilagimod alpha | 3 | ||
25/08/2020 | ! | Appendix 4E & 2020 Full Year Statutory Accounts | 85 | |
18/08/2020 | ! | Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study | 2 | |
17/08/2020 | Immutep Investor Update | 14 | ||
11/08/2020 | ! | Immutep Granted US Patent for Eftilagimod Alpha | 2 | |
11/08/2020 | Lapse of Unlisted Options | 1 | ||
27/07/2020 | Change in substantial holding | 6 | ||
23/07/2020 | ! | Immutep Quarterly Activities Report & Appendix 4C | 9 | |
21/07/2020 | Change in substantial holding | 6 | ||
15/07/2020 | ! | Immutep Announces United States Patent Grant for IMP701 Antibody | 2 | |
29/06/2020 | ! | Immutep Completes Recruitment for Part A of TACTI-002 trial | 3 | |
22/06/2020 | ! | Immutep receives A$1,437,826 R&D Tax Incentive | 2 | |
01/06/2020 | ! | Immutep announces improving data from TACT I - 002 ph II trial | 4 | |
01/06/2020 | ! | Immutep Reports First Result from INSIGHT - 004 Study | 3 | |
29/05/2020 | ! | Immutep Receives $3.6M R&D French Tax Incentive | 2 | |
27/05/2020 | Immutep webcast to present new data from 2020 ASCO meeting | 2 | ||
07/05/2020 | Becoming a substantial holder from AEF | 4 | ||
07/05/2020 | ! | Immutep Granted Japanese Patent for Eftilagimod Alpha | 2 | |
07/05/2020 | Change in substantial holding | 6 | ||
05/05/2020 | Cleansing Notice | 1 | ||
04/05/2020 | Appendix 2A | 16 | ||
01/05/2020 | Immutep presents at NWR Virtual Small Cap Health Conference | 1 | ||
30/04/2020 | ! | INSIGHT-004 and TACTI-002 data to be presented at ASCO | 2 | |
29/04/2020 | ! | Proposed issue of Securities - IMM | 5 | |
29/04/2020 | Immutep Investor Presentation | 51 | ||
29/04/2020 | ! | Immutep completes A$12 million placement | 3 | |
28/04/2020 | ! | Immutep Reports Positive Phase II TACTI-002 Data | 5 | |
27/04/2020 | ! | Trading Halt | 2 | |
22/04/2020 | Enrollment completed for the INSIGHT-004 Study | 3 | ||
20/04/2020 | ! | Immutep March Quarterly Activities Report & Appendix 4C | 10 | |
16/04/2020 | ! |
Immutep advances its LAG-3 agonist for autoimmune diseases
|
2 | |
14/04/2020 | ! |
Immutep presents TACTI-002 data at AACR Virtual Meeting
|
2 | |
08/04/2020 | ! |
EOC Pharma confirms plans to advance Efti in China for MBC
|
2 | |
26/03/2020 | ! | 20 | ||
25/03/2020 | ! | 4 | ||
20/03/2020 | 3 | |||
16/03/2020 |
Change of Director's Interest Notice - Mr Chamberlain
|
2 | ||
09/03/2020 | Immutep receives 2nd IND approval for efti from US FDA | 2 | ||
02/03/2020 | Change in substantial holding | 6 | ||
25/02/2020 | Immutep Clinical Update & Results Global Webcast Slides | 23 | ||
21/02/2020 | Change in substantial holding | 6 | ||
21/02/2020 | ! | Half Yearly Report and Accounts | 30 | |
19/02/2020 | ! | Immutep reports positive TACTI-002 data | 5 | |
05/02/2020 | Change in substantial holding | 6 | ||
04/02/2020 | Immutep to present TACTI-002 data at German Cancer Congress | 2 | ||
29/01/2020 | ! | Immutep Activities Report | 4 | |
29/01/2020 | ! | Appendix 4C - Quarterly | 5 | |
10/01/2020 | Immutep Corporate Presentation | 33 | ||
09/01/2020 | ! | Immutep expands Part C of TACTI-002 due to positive data | 2 | |
06/01/2020 | Change in substantial holding | 6 | ||
02/01/2020 | Change of Director's Interest Notice | 3 | ||
02/01/2020 | Appendix 3B | 15 | ||
19/12/2019 | ! | INSIGHT-004 clinical trial update | 3 | |
09/12/2019 | Change of Director's Interest Notice - Mr Meyers | 3 | ||
09/12/2019 | Change of Director's Interest Notice - Dr Howard | 2 | ||
09/12/2019 | Change of Director's Interest Notice - Mr Voigt | 3 | ||
02/12/2019 | Appendix 3B | 16 | ||
22/11/2019 | Immutep Investor Update | 13 | ||
14/11/2019 | ! | Immutep announces European patent grant for LAG525 antibody | 2 | |
08/11/2019 | ! | IMM presents positive interim phase 2 TACTI-002 data at SITC | 3 | |
01/11/2019 | Update - Consolidation Split - IMM | 4 | ||
01/11/2019 | 2019 AGM CEO Presentation | 24 | ||
01/11/2019 | 2019 AGM Chairman's Address | 3 | ||
01/11/2019 | Results of Annual General Meeting | 2 | ||
31/10/2019 | Consolidation/Split - IMM | 4 | ||
28/10/2019 | ! | Operational Update | 3 | |
24/10/2019 | Change in substantial holding | 6 | ||
23/10/2019 | ! | Appendix 4C - quarterly | 5 | |
15/10/2019 | ! | Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma |
23 | |
10/10/2019 | ! | Immutep receives A$2.5M R&D French Tax Incentive | 2 | |
10/10/2019 | Immutep to present data at upcoming Industry Conferences | 2 | ||
04/10/2019 | Change of Director's Interest Notice - Mr Chamberlain | 3 | ||
04/10/2019 | Change of Director's Interest Notice - Mr Meyers | 3 | ||
03/10/2019 | Appendix 3B | 15 | ||
30/09/2019 | Immutep Investor Presentation | 39 | ||
30/09/2019 | Notice of Annual General Meeting/Proxy Form | 31 | ||
30/09/2019 | Annual Report to shareholders | 82 | ||
30/09/2019 | Appendix 4G & Corporate Governance Statement | 32 | ||
26/09/2019 | ! | Immutep expands Part A of TACTI-002 due to positive data | 3 | |
24/09/2019 | Annual Report filed on Form 20-F with SEC | 199 | ||
23/09/2019 | ! | Immutep to receive GBP4M Milestone Payment from GSK | 2 | |
17/09/2019 | ! | Japanese patent granted for LAG525 antibody | 2 | |
22/08/2019 | ! | Immutep granted European patent for IMP321 in cancer | 2 | |
20/08/2019 | ! | Appendix 4E & 2019 Full Year Statutory Accounts | 83 | |
13/08/2019 | Ceasing to be a substantial holder from AEF | 3 | ||
09/08/2019 | Change in substantial holding | 5 | ||
07/08/2019 | Change of Director's Interest Notice - Mr Chamberlain | 2 | ||
07/08/2019 | Change of Director's Interest Notice - Mr Voigt | 2 | ||
06/08/2019 | Immutep completes fully underwritten A$6M Entitlement Offer | 2 | ||
01/08/2019 | ! | Entitlement Offer Results & Shortfall Notification | 2 | |
26/07/2019 | ! | Operational Update | 4 | |
26/07/2019 | ! | Appendix 4C - quarterly | 5 | |
19/07/2019 | Becoming a substantial holder from AEF | 3 | ||
19/07/2019 | Change in substantial holding | 6 | ||
17/07/2019 | Mailing of Offer Booklet for Entitlement Offer | 1 | ||
17/07/2019 | Cleansing Notice | 1 | ||
17/07/2019 |
Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b)
|
1 | ||
09/07/2019 |
Cleansing Notice
|
1 | ||
09/07/2019 |
Letter to Ineligible Shareholders
|
2 | ||
09/07/2019 |
Letter to Eligible Shareholders
|
3 | ||
09/07/2019 |
Appendix 3B
|
14 | ||
09/07/2019 | ! |
Immutep Entitlement Offer Booklet
|
56 | |
09/07/2019 | ! |
Immutep Capital Raising Presentation
|
27 | |
09/07/2019 | ! |
Immutep raises A$10M via placement & entitlement offer
|
4 | |
05/07/2019 | ! | 2 | ||
25/06/2019 | ! |
Immutep completes recruitment of AIPAC trial in MBC
|
3 | |
25/06/2019 |
Immutep hosts Key Opinion Leader Call
|
2 | ||
21/06/2019 | ! |
Immutep granted Australian patent for eftilagimod alpha
|
2 | |
13/06/2019 | ! | 2 | ||
06/06/2019 | ! | 3 | ||
03/06/2019 | 14 | |||
03/06/2019 |
Immutep Poster Presentation at ASCO
|
3 | ||
23/05/2019 | ! | 2 | ||
17/05/2019 | ! | 2 | ||
10/05/2019 | 2 | |||
08/05/2019 | 67 | |||
30/04/2019 | ! | 4 | ||
24/04/2019 | ! | 5 | ||
02/04/2019 | 29 | |||
27/03/2019 | 2 | |||
26/03/2019 | 10 | |||
25/03/2019 | 13 | |||
22/03/2019 | ! | 2 | ||
19/03/2019 | 2 | |||
08/03/2019 | ! | 2 | ||
07/03/2019 | ! | 1 | ||
06/03/2019 | ! | 4 | ||
06/03/2019 | ! | 3 | ||
04/03/2019 | 2 | |||
27/02/2019 | 29 | |||
26/02/2019 | 2 | |||
25/02/2019 | 18 | |||
31/01/2019 | 14 | |||
24/01/2019 | ! |
Appendix 4C - quarterly
|
5 | |
07/01/2019 | ! | 3 | ||
04/01/2019 | 3 | |||
04/01/2019 | 4 | |||
02/01/2019 |
Appendix 3B
|
15 | ||
24/12/2018 | Becoming a substantial holder | 4 | ||
21/12/2018 | Disclosure Under LR 3.10.5A and 7.1A.4(b) | 2 | ||
21/12/2018 | Cleansing Notice | 1 | ||
21/12/2018 | Appendix 3B | 14 | ||
20/12/2018 | ! | Cleansing prospectus for issue of warrants | 46 | |
19/12/2018 | ! | Immutep announces US$5.2 million capital raising | 3 | |
29/11/2018 | ! | European patent granted for IMP321 & antibody combinations | 2 | |
28/11/2018 | ! | Immutep granted European patent for IMP321 | 2 | |
27/11/2018 | ! | Immutep presents new TACTI-mel data at ICI Europe Summit | 3 | |
26/11/2018 | Change of Director's Interest Notice - Dr Howard | 2 | ||
21/11/2018 | Appendix 3B | 14 | ||
16/11/2018 | Results of Meeting | 3 | ||
16/11/2018 | 2018 AGM CEO Presentation | 23 | ||
16/11/2018 | 2018 AGM Chairman's Address | 3 | ||
12/11/2018 | ! | Positive interim TACTI-mel data presented at SITC | 3 | |
01/11/2018 | ! | Operational Update | 4 | |
30/10/2018 | AusBiotech Invest presentation slides | 11 | ||
25/10/2018 | ! | Appendix 4C - quarterly | 5 | |
22/10/2018 | Annual Report filed on Form 20-F with SEC | 127 | ||
11/10/2018 | Notice of Annual General Meeting/Proxy Form | 27 | ||
11/10/2018 | Annual Report to shareholders | 80 | ||
11/10/2018 | Appendix 4G & Corporate Governance Statement | 32 | ||
04/10/2018 | Appendix 3B & cleansing notice | 15 | ||
02/10/2018 | Change of Director's Interest Notice - Mr Chamberlain | 3 | ||
02/10/2018 | Change of Director's Interest Notice - Mr Meyers | 3 | ||
02/10/2018 | Appendix 3B & cleansing notice | 15 | ||
02/10/2018 | Ceasing to be a substantial holder from AEF | 3 | ||
02/10/2018 | Immutep to present at SITC 2018 | 2 | ||
28/09/2018 | Appendix 3B & cleansing notice | 14 | ||
27/09/2018 | Appendix 3B & cleansing notice | 14 | ||
27/09/2018 | Change in substantial holding from AEF | 3 | ||
26/09/2018 | Immutep to present at Ladenburg Thalmann conference | 1 | ||
24/09/2018 | ! | Immutep enters into collaboration with Pfizer & Merck KGaA | 4 | |
07/09/2018 | Immutep presentation for BioCentury NewsMakers conference | 29 | ||
03/09/2018 | Change in substantial holding from AEF | 3 | ||
03/09/2018 | ! | Progress towards clinical development of IMP761 | 2 | |
21/08/2018 | ! | Appendix 4E & 2018 Full Year Statutory Accounts | 82 | |
21/08/2018 | ! | Immutep receives A$1.9M from French R&D tax cash rebate | 2 | |
16/08/2018 | Immutep to present at BioCentury NewsMakers conference | 2 | ||
07/08/2018 | ! | Immutep secures Canadian patent grant for IMP731 antibody | 2 | |
07/08/2018 | ! | TACTI-mel Patient Recruitment Complete & Operational Update | 3 | |
31/07/2018 | ! | Immutep receives IND approval from US FDA for IMP321 | 2 | |
30/07/2018 | ! | Appendix 4C - quarterly | 5 | |
02/07/2018 | ! | Immutep submits IND application with FDA | 2 | |
19/06/2018 | Investor Update | 13 | ||
19/06/2018 | ! | Mid-point of patient enrolment reached in AIPAC trial | 2 | |
04/06/2018 | Immutep Poster Presentations at ASCO | 2 | ||
30/05/2018 | ! | Webcast slides for TACTI-mel clinical trial data | 25 | |
30/05/2018 | ! | New Data from Ongoing TACTI-mel Study | 2 | |
25/05/2018 | 3rd Annual Advances in Immuno-Oncology Congress Presentation | 37 | ||
17/05/2018 | Webcast to discuss interim results from TACTI-mel | 3 | ||
15/05/2018 | Response to ASX Price Query | 3 | ||
04/05/2018 | Immutep to present at ASCO | 2 | ||
23/04/2018 | Appendix 4C | 5 | ||
13/04/2018 | Appendix 3B | 13 | ||
13/04/2018 | Completion of Share Purchase Plan | 2 | ||
03/04/2018 | ! | Operational Update | 2 |